159 related articles for article (PubMed ID: 18502409)
1. Varied presentation of the Thomsen-Friedenreich disaccharide tumor-associated carbohydrate antigen on gold nanoparticles.
Sundgren A; Barchi JJ
Carbohydr Res; 2008 Jul; 343(10-11):1594-604. PubMed ID: 18502409
[TBL] [Abstract][Full Text] [Related]
2. Synthesis and cell-selective antitumor properties of amino acid conjugated tumor-associated carbohydrate antigen-coated gold nanoparticles.
Biswas S; Medina SH; Barchi JJ
Carbohydr Res; 2015 Mar; 405():93-101. PubMed ID: 25556664
[TBL] [Abstract][Full Text] [Related]
3. Design and synthesis of multifunctional gold nanoparticles bearing tumor-associated glycopeptide antigens as potential cancer vaccines.
Brinãs RP; Sundgren A; Sahoo P; Morey S; Rittenhouse-Olson K; Wilding GE; Deng W; Barchi JJ
Bioconjug Chem; 2012 Aug; 23(8):1513-23. PubMed ID: 22812418
[TBL] [Abstract][Full Text] [Related]
4. Isolipoic acid-linked gold nanoparticles bearing the thomsen friedenreich tumor-associated carbohydrate antigen: Stability and
Mondal UK; Barchi JJ
Front Chem; 2022; 10():1002146. PubMed ID: 36300019
[TBL] [Abstract][Full Text] [Related]
5. Direct demonstration of increased expression of Thomsen-Friedenreich (TF) antigen in colonic adenocarcinoma and ulcerative colitis mucin and its concealment in normal mucin.
Campbell BJ; Finnie IA; Hounsell EF; Rhodes JM
J Clin Invest; 1995 Feb; 95(2):571-6. PubMed ID: 7860740
[TBL] [Abstract][Full Text] [Related]
6. Synthesis of the Thomsen-Friedenreich-antigen (TF-antigen) and binding of Galectin-3 to TF-antigen presenting neo-glycoproteins.
Hoffmann M; Hayes MR; Pietruszka J; Elling L
Glycoconj J; 2020 Aug; 37(4):457-470. PubMed ID: 32367478
[TBL] [Abstract][Full Text] [Related]
7. Synthesis of a MUC1-glycopeptide-BSA conjugate vaccine bearing the 3'-deoxy-3'-fluoro-Thomsen-Friedenreich antigen.
Hoffmann-Röder A; Johannes M
Chem Commun (Camb); 2011 Sep; 47(35):9903-5. PubMed ID: 21818465
[TBL] [Abstract][Full Text] [Related]
8. Direct targeted glycation of the free sulfhydryl group of cysteine residue (Cys-34) of BSA. Mapping of the glycation sites of the anti-tumor Thomsen-Friedenreich neoglycoconjugate vaccine prepared by Michael addition reaction.
Demian WL; Kottari N; Shiao TC; Randell E; Roy R; Banoub JH
J Mass Spectrom; 2014 Dec; 49(12):1223-33. PubMed ID: 25476939
[TBL] [Abstract][Full Text] [Related]
9. A Stable Gold Nanoparticle-Based Vaccine for the Targeted Delivery of Tumor-Associated Glycopeptide Antigens.
Trabbic KR; Kleski KA; Barchi JJ
ACS Bio Med Chem Au; 2021 Dec; 1(1):31-43. PubMed ID: 34927166
[TBL] [Abstract][Full Text] [Related]
10. Utilization of novel lectin-conjugated Au nanoparticles as Thomsen-Friedenreich onco-antigen target for in vitro cytotoxicity and apoptosis induction in leukemic cell line.
Akram SM; Al-Saffar AZ; Hadi NA; Akram SM
Life Sci; 2022 Dec; 311(Pt A):121163. PubMed ID: 36368415
[TBL] [Abstract][Full Text] [Related]
11. Molecular recognition of the Thomsen-Friedenreich antigen-threonine conjugate by adhesion/growth regulatory galectin-3: nuclear magnetic resonance studies and molecular dynamics simulations.
Yongye AB; Calle L; Ardá A; Jiménez-Barbero J; André S; Gabius HJ; Martínez-Mayorga K; Cudic M
Biochemistry; 2012 Sep; 51(37):7278-89. PubMed ID: 22916968
[TBL] [Abstract][Full Text] [Related]
12. Cancer targeting with biomolecules: a comparative study of photodynamic therapy efficacy using antibody or lectin conjugated phthalocyanine-PEG gold nanoparticles.
Obaid G; Chambrier I; Cook MJ; Russell DA
Photochem Photobiol Sci; 2015 Apr; 14(4):737-47. PubMed ID: 25604735
[TBL] [Abstract][Full Text] [Related]
13. Occurrence of the human tumor-specific antigen structure Galβ1-3GalNAcα- (Thomsen-Friedenreich) and related structures on gut bacteria: prevalence, immunochemical analysis and structural confirmation.
Henderson G; Ulsemer P; Schöber U; Löffler A; Alpert CA; Zimmermann-Kordmann M; Reutter W; Karsten U; Goletz S; Blaut M
Glycobiology; 2011 Oct; 21(10):1277-89. PubMed ID: 21551457
[TBL] [Abstract][Full Text] [Related]
14. Structural insights into the recognition mechanism between an antitumor galectin AAL and the Thomsen-Friedenreich antigen.
Feng L; Sun H; Zhang Y; Li DF; Wang DC
FASEB J; 2010 Oct; 24(10):3861-8. PubMed ID: 20530247
[TBL] [Abstract][Full Text] [Related]
15. Anti-Thomsen-Friedenreich-Ag (anti-TF-Ag) potential for cancer therapy.
Almogren A; Abdullah J; Ghapure K; Ferguson K; Glinsky VV; Rittenhouse-Olson K
Front Biosci (Schol Ed); 2012 Jan; 4(3):840-63. PubMed ID: 22202095
[TBL] [Abstract][Full Text] [Related]
16. Synthesis and Immunological Evaluation of Disaccharide Bearing MUC-1 Glycopeptide Conjugates with Virus-like Particles.
Wu X; McKay C; Pett C; Yu J; Schorlemer M; Ramadan S; Lang S; Behren S; Westerlind U; Finn MG; Huang X
ACS Chem Biol; 2019 Oct; 14(10):2176-2184. PubMed ID: 31498587
[TBL] [Abstract][Full Text] [Related]
17. Monoclonal antibody BW835 defines a site-specific Thomsen-Friedenreich disaccharide linked to threonine within the VTSA motif of MUC1 tandem repeats.
Hanisch FG; Stadie T; Bosslet K
Cancer Res; 1995 Sep; 55(18):4036-40. PubMed ID: 7545084
[TBL] [Abstract][Full Text] [Related]
18. Determination of thermodynamic parameters of Xerocomus chrysenteron lectin interactions with N-acetylgalactosamine and Thomsen-Friedenreich antigen by isothermal titration calorimetry.
Damian L; Fournier D; Winterhalter M; Paquereau L
BMC Biochem; 2005 Jun; 6():11. PubMed ID: 15929788
[TBL] [Abstract][Full Text] [Related]
19. Thermodynamic Switch in Binding of Adhesion/Growth Regulatory Human Galectin-3 to Tumor-Associated TF Antigen (CD176) and MUC1 Glycopeptides.
Rodriguez MC; Yegorova S; Pitteloud JP; Chavaroche AE; André S; Ardá A; Minond D; Jiménez-Barbero J; Gabius HJ; Cudic M
Biochemistry; 2015 Jul; 54(29):4462-74. PubMed ID: 26129647
[TBL] [Abstract][Full Text] [Related]
20. Immune response to Thomsen-Friedenreich disaccharide and glycan engineering.
Irazoqui FJ; Sendra VG; Lardone RD; Nores GA
Immunol Cell Biol; 2005 Aug; 83(4):405-12. PubMed ID: 16033536
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
